The Ebola virus has killed hundreds of thousands of people in West Africa, but it has also been devastating for some of the biggest companies in the world.

The Ebola virus is spreading like wildfire, and a number of major pharmaceutical companies are struggling to keep up.

While some of these companies are doing a good job at curbing the spread of the virus, others are struggling.

The pharmaceutical giant Pfizer, for example, announced it will discontinue all of its new therapies, including some of its older drugs, due to Ebola, which has killed more than 7,000 people in the last three months.

On Friday, the company said it would temporarily suspend all of the treatments it had already announced and said it had to reassess the risk of continued exposure to the virus.

The drugmaker, which makes Sovaldi and Daraprim, is among the biggest purchasers of drugs in the United States, and Pfizer said in a statement it would spend more than $3 billion to help its U.S. customers fight the virus with new therapies.

Pfizer has already spent $1.2 billion to develop drugs to treat Ebola.

Its other biggest drugmakers, Johnson & Johnson and Eli Lilly, have also spent billions on Ebola-related research.

Pfeiffer-Weil, which is in the midst of a $4 billion expansion in its U-Maine headquarters, has also made several major investments in new vaccines and therapeutics.

Its CEO, Peter Boesseler, told reporters in January that the company was ready to “make some major decisions” if it found a way to stop the virus from spreading.PFEIFER, which owns a wide range of medical devices and medical devices components, has spent more than half a billion dollars on vaccines and diagnostics in Africa and is working with more than 100 countries to develop them, Boesse said.

“We believe that our products and our business model are the most effective way to fight the Ebola pandemic, and that our investments in the continent will be successful,” he said.PFIELDS COLLABORING AND MEDICARE-INFLUENCED REPORTSPfeifer- Weil has not publicly disclosed the investments, but in January it said it was working with the governments of Sierra Leone, Liberia, Guinea, Nigeria, Senegal and Guinea to develop Ebola-fighting vaccines and treatment methods.

In February, the group also announced it would collaborate with the government of Senegal to develop a vaccine for Ebola.

The group also said it is working to develop the vaccines and treatments for people who have recovered from the virus in Sierra Leone and Guinea.

The company said in March that it is planning to begin a “highly targeted and integrated vaccine production program” in Guinea.PFELICIA’S PRICE TOUGHLY COLLAPSINGIn response to the pandemic and the potential for more infections, the prices of many of the drugs Pfizer sells to patients have been on the rise.

Pfrase’s annual sales for the year ending March 2017 rose to $5.9 billion from $4.9bn in the year-ago period, while Sovaldi was up $3.4 billion to $7.5 billion, Pfizer CEO Peter Biesseler said in January.

Pfleiderer, a drug used to treat malaria, has increased in price from $8 a month earlier to $30.50 a month later, and its price has doubled in the past year, Biesselser said at the time.

Pfluger, a medicine used to fight HIV, also increased in prices from $7 a month ago to $18.50 this year, and the drug has doubled its price in the same period.

The price of Darapress, an antiviral drug that treats the virus and is sold under a brand name by Pfizer in the U.K., has also risen, to $20.50 from $11.70.

Darapress and Pfizers other generic versions of the drug, which are manufactured by Johnson &amys, are cheaper than the Darapresis.

In April, Pfizers and Johnson &Johnson announced that they would buy a 49.9 percent stake in AstraZeneca, which manufactures the drugs Darapristone and Pertussis.

Astra is the largest generic drugmaker in the European Union, accounting for about half of all generic medicines sold in Europe.

Johnson &amp’jansen is one of the world’s largest drugmakers.

In March, it announced it was buying a 61.7 percent stake from Astra in a $2.5-billion deal.

The deal also included an undisclosed amount of debt.

Johnson &ams was not immediately available for comment.

B&amps said on Thursday that it had reached an agreement with Astra to merge its